The effect of combined stanozolol-phenformin therapy was assessed in 21 patients with Types IIB, IV and V primary hyperlipoproteinaemias. Three-months treatment resulted in marked reduction of serum triglycerides, less distinct decrease of serum cholesterol and significant augmentation of blood fibrinolytic activity.
SznajdermanMBerentHRymaszewskiZ. The effect of combined treatment with phenformin and stanozolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia. Atherosclerosis1974; 19: 153–159.
2.
HarsantPR. A review of the mode of action of phenformin. Postgrad Med J1969; suppl. May, 20–23.
3.
KuePTQuickRE. Improvement of hypertriglyceridemia by anabolic agents in primary type I hyperlipoproteinaemia. Circulation1970; 3: 66–70.
4.
ChakrabartiRFearnleyGR. Phenformin plus ethyloestrenol in survivors of myocardial infarction. Lancet1972; 2: 556–559.
5.
AndersonP. Hyperlipidaemia and reduced fibrinolytic activity associated with thromboembolic complications in a family. Acta Med Scand1976; 200: 289–291.
